Krystal Biotech, Inc. (KRYS) stock analysis
Close on Nov 11, 2026Market cap $9.14BP/E 41.9Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Mixed11 of 30 checks passed
Krystal Biotech passes 11 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 1/6
- Past performance
- 3/6
- Financial health
- 6/6
- Dividend
- 0/6
What stands out
Return on capital over 10%
Return on invested capital was 42.6%, above the 10% that usually covers the cost of capital.
No debt
Krystal Biotech has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
What to watch
Margin of safety under 20%
The price is 43.1% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $308.81 is above our fair value estimate of $215.73.
Return on equity under 15%
Return on equity was 17.5% over the last twelve months and averaged -2.0% over five years; we look for 15% on both.
P/E above the industry
Krystal Biotech's P/E of 41.9 is above the Drugs median of 25.1.
Valuation1/6
P/E against its history
Not enough price and earnings history to compare.
P/E above the industry
Krystal Biotech's P/E of 41.9 is above the Drugs median of 25.1.
EV/EBITDA below its 5-year median
Krystal Biotech's EV/EBITDA of 36.2 is below its 5-year median of 45.0.
P/B above the industry
Krystal Biotech's price-to-book of 6.37 is above the Drugs median of 2.29.
Trading above fair value
The share price of $308.81 is above our fair value estimate of $215.73.
Margin of safety under 20%
The price is 43.1% above fair value, so there is no margin of safety.
Growth1/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growing faster than the industry
Revenue grew 26.0% over the last twelve months; the Drugs median is 8.0%.
Guidance issued
The latest outlook (FY 2026 Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense (1), Nov 2, 2026) was issued for the first time, so it neither adds nor takes away points.
Gross margin trend
This company does not report gross profit.
Past performance3/6
Return on equity under 15%
Return on equity was 17.5% over the last twelve months and averaged -2.0% over five years; we look for 15% on both.
Return on capital over 10%
Return on invested capital was 42.6%, above the 10% that usually covers the cost of capital.
Return on equity above the industry
Krystal Biotech's return on equity of 17.5% is above the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin above the industry
Krystal Biotech's net margin of 47.9% is above the Drugs median of -53.0%.
Financial health6/6
No debt
Krystal Biotech has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 7.89 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 38.13; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Krystal Biotech has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$215.73
The share price is 43% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 25.1× | – | 25.1× | $184.89 | 47% |
| EV/EBITDA | 30.0× | 45.0× | 17.1× | $261.41 | 41% |
| P/B | 3.7× | 5.1× | 2.3× | $179.17 | 12% |
| Earnings powerleft out, too far from the others | 9.1% cost of equity | – | – | $25.69 | – |
| Fair value | $215.73 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Drugs median 25.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $99.66M
- Value traded per 1% price move
- $52.38M
Downside
Low risk
- Typical loss in a bad month
- 12.3%
- Volatility (annualized)
- 39%
- Sharpe ratio, 1 year
- 1.28
- Beta to the S&P 500 (5Y)
- 0.84
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +33.9% | – | – | – | |
| Operating income | +145.3% | – | – | – | |
| Net income | +129.7% | – | – | – | |
| EPS, diluted | +128.0% | – | – | – | |
| Free cash flow | +58.5% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -13.0% | 18.9% | |
| Return on assets | – | -12.4% | 17.1% | |
| Current ratio | 50.44 | 17.80 | 9.95 | |
| Capex to revenue | – | – | 3.1% | |
| Diluted shares | 1M | 19M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Krystal Biotech generated $561.60M from operations and spent $149.30M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 52.6% | 0.33× | 1.10× | 18.9% |
| FY2024 | 30.7% | 0.31× | 1.09× | 10.3% |
| FY2023 | 21.6% | 0.07× | 1.06× | 1.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$204.83M
- Cash generatingOperating cash flow above zero$200.87M
- Return on assets improvedROA up on the prior year10.9% → 19.4%
- Earnings backed by cashOperating cash flow above net income$200.87M vs $204.83M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.28 → 9.95
- No dilutionShare count did not rise30M → 30M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.35 → 0.37
See a number that looks wrong?